12 Infants Die in Clinical Trial For RSV Injection Approved by FDA Panel

A U.S. Food & Drug Administration (FDA) panel recently recommended approval for AstraZeneca’s new monoclonal antibody, which supposedly protects infants and toddlers up to age 2 from respiratory syncytial virus (RSV).

The drug, manufactured by AstraZeneca and Sanofi, is designed to be given to infants in a single shot at birth or just before the start of a baby’s first RSV season.

It can also be given in a larger dose in a second RSV season in children who are highly vulnerable.

Although the drug, nirsevimab, isn’t a ‘vaccine,’ it’s still a dangerous injection that can catastrophically harm infants and toddlers.

In the drug’s clinical trial, 12 infant deaths were recorded.

The FDA committee said the deaths were “unrelated” to the antibody.

https://wltreport.com/2023/06/21/12-infants-die-in-clinical-trial-for-rsv-injection-approved-by-fda-panel/